BCL2 and B-cell chronic lymphocytic leukemia: Among the BH3-mimetics, venetoclax (also known as ABT-199), a potent and selective inhibitor of BCL-2, was recently approved by the US Food and Drug Administration (FDA) for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) with 17p deletion based on its favorable safety profile and high response rates [10].